The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Evaluating the safety and efficacy of novel anti-CD7 universal CAR-T therapy in R/R T-ALL and T-LBL
Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, and Hebei Yanda Lu Daopei Hospital, Langfang, China, describes the results of a Phase I trial (NCT04620655) assessing the universal CAR-T cell (UCAR-T) RD13-01 in patients with heavily pre-treated, relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The study reported a benefit with RD13-01 with respect to complete remission (CR), with high rates of measurable residual disease (MRD) negativity. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
